×
| Stock | Total Income | Net Profit | Net Sales | EPS | Market Cap (in Cr) | P/E |
|---|---|---|---|---|---|---|
| FABINO ENTERPRISES LIMITED | NA | NA | NA | NA | 5.46 | 91.0 |
| Triochem Products Ltd., | 3.25 | -4.52 | NA | -18.44 | 0 | |
| Fredun Pharmaceuticals Limited | 1,674.07 | 70.72 | 1,654.38 | 14.98 | 453.0 | 21.8 |
| BROOKS LABORATORIES LTD. | 239.37 | 13.72 | 233.17 | 0.51 | 439 | 144.0 |
| LYKA LABS LTD. | 312.37 | 13.06 | 305.17 | 0.36 | 410 | 51.8 |
Fredun Pharmaceuticals Limited, with Security Code 539730, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.
| Metrics | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 77.6 | 79.7 | 61.2 | 81.5 | 86.7 | 117.2 | 77.5 | 106.9 | 101.8 | 165.4 |
| Expenses | 70.6 | 67.5 | 54.4 | 72.4 | 76.5 | 106.9 | 68.3 | 93.4 | 89.5 | 149.9 |
| Operating Profit | 7.0 | 12.2 | 6.8 | 9.1 | 10.2 | 10.3 | 9.2 | 13.5 | 12.4 | 15.5 |
| OPM % | 9.01% | 15.28% | 11.09% | 11.17% | 11.73% | 8.83% | 11.87% | 12.62% | 12.15% | 9.39% |
| Other Income | 0.3 | 0.1 | 0.8 | 0.5 | 0.4 | 0.8 | 1.3 | 0.5 | 0.9 | 2.0 |
| Interest | 2.0 | 3.6 | 2.6 | 2.9 | 3.8 | 4.4 | 3.9 | 5.3 | 5.0 | 8.1 |
| Depreciation | 0.7 | 0.7 | 0.9 | 0.9 | 1.0 | 1.0 | 1.0 | 1.1 | 1.1 | 1.3 |
| Profit before tax | 4.6 | 8.0 | 4.1 | 5.8 | 5.8 | 5.8 | 5.5 | 7.6 | 7.1 | 8.1 |
| Tax % | -25.2% | -51.4% | -41.1% | -31.8% | -26.7% | -13.3% | -25.2% | -43.6% | -25.3% | -11.2% |
| Net Profit | 3.5 | 3.9 | 2.4 | 3.9 | 4.2 | 5.1 | 4.1 | 4.3 | 5.3 | 7.1 |
| EPS in Rs | 7.66 | 8.59 | 5.24 | 8.4 | 8.99 | 10.77 | 8.79 | 9.05 | 11.29 | 0 |
| Metrics | Mar 2025 |
|---|---|
| Sales | 165.4 |
| Expenses | 150.1 |
| Operating Profit | 15.3 |
| OPM % | 9.26% |
| Other Income | 2.0 |
| Interest | 8.1 |
| Depreciation | 1.8 |
| Profit before tax | 7.3 |
| Tax % | -16.5% |
| Net Profit | 6.0 |
| EPS in Rs | 0 |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 32% |
| 5 Years: | 29% |
| 3 Years: | 38% |
| TTM: | 31% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 52% |
| 5 Years: | 28% |
| 3 Years: | 98% |
| TTM: | 30% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 36% |
| 3 Years: | -6% |
| 1 Year: | -13% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 0% |
| 3 Years: | 0% |
| TTM: | 0% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 0% |
| 3 Years: | 0% |
| TTM: | 0% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 0% |
| 3 Years: | 0% |
| 1 Year: | 0% |
Recent Bets
|
Date
|
Stock
|
Party
|
Deal
|
Acq. Mode
|
Trans.
|
Quan.
|
Price
|
Value
|
|---|